EM1710H "Actionable Tumor Genomics: Ready for Cancer Care & Clinical Trials?" (IM GR-102717)
To discuss the role of genomic profiling of tumors in identifying tumor vulnerabilities that inform cancer treatment and/or enrollment in clinical trials with targeted therapies.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Understand the role of next gen sequencing in drug development
- Understand there is a variety of mechanism of acquired drug resistance to targeted therapies that can be identified by tumor genomic profiling
- Understand the role of plasma tumor cell-free DNA sequencing in clinical investigation
Carlos L. Arteaga, M.D.
Professor of Internal Medicine
Director, Harold C. Simmons Comprehensive Cancer Center
The Lisa K. Simmons Distinguished Chair in Comprehensive Oncology
Associate Dean of Oncology Programs
Pamela Hearn Isom Visiting Professor
- 1.00 AMA